MGC Pharmaceuticals Shares Rise After Study Completion for CimetrA
10 1월 2023 - 6:00PM
Dow Jones News
By Kyle Morris
Shares in MGC Pharmaceuticals Ltd. rose 13% in early trade
Tuesday after the company said that it has completed the
preclinical rodent studies on CimetrA, an important step ahead of
submission to the U.S. Food and Drug Administration for
Investigational New Drug approval.
The pharmaceutical company said that CimetrA is its proprietary
investigational medicinal product which has demonstrated
anti-inflammatory and immunomodulating properties.
Shares at 0820 GMT were up 0.08 pence at 0.65 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 10, 2023 03:45 ET (08:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
MGC Pharmaceuticals (ASX:MXC)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
MGC Pharmaceuticals (ASX:MXC)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
